TARGETING THE CHK1-STAT3-CIP2A AXIS TO TREAT GLIOBLASTOMA (GBM)

靶向 CHK1-STAT3-CIP2A 轴治疗胶质母细胞瘤 (GBM)

• 批准号: nhmrc : GNT1090035
• 负责人: Dr Anchit Khanna
• 金额: $ 30.94万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-chk1-stat3-glioblastoma-gbm/1345781
• 关键词: TARGETING; CHK1; STAT3; CIP2A; AXIS

Glioblastoma (GBM is a high-grade brain tumour for which current treatments are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified a DNA-damage signalling pathway and demonstrated that perturbation of the pathway significantly reduces tumour growth. We plan to target key proteins of the recently identified pathway and validate these findings using tumour cells directly from GBM patients and relevant animal models of human GBM.

胶质母细胞瘤（GBM）是一种高级别的脑肿瘤，目前的治疗是不够的。肿瘤复发几乎是不可避免的，平均预期寿命以月为单位。我们已经确定了一个DNA损伤信号通路，并证明该通路的扰动显着降低肿瘤生长。我们计划靶向最近确定的途径的关键蛋白，并使用直接来自GBM患者的肿瘤细胞和人类GBM的相关动物模型来验证这些发现。